236 related articles for article (PubMed ID: 9069448)
1. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.
Brown JH; Murphy BG; Douglas AF; Short CD; Bhatnagar D; Mackness MI; Hunt LP; Doherty CC; Durrington PN
Nephron; 1997; 75(3):277-82. PubMed ID: 9069448
[TBL] [Abstract][Full Text] [Related]
2. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy.
Brown JH; Anwar N; Short CD; Bhatnager D; Mackness MI; Hunt LP; Durrington PN
Nephrol Dial Transplant; 1993; 8(9):863-7. PubMed ID: 8255521
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients.
Wheeler DC; Morgan R; Thomas DM; Seed M; Rees A; Moore RH
Transpl Int; 1996; 9(3):221-6. PubMed ID: 8723190
[TBL] [Abstract][Full Text] [Related]
4. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?
Webb AT; Reaveley DA; O'Donnell M; O'Connor B; Seed M; Brown EA
Lancet; 1993 Jan; 341(8840):268-70. PubMed ID: 8093917
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients.
Azrolan N; Brown CD; Thomas L; Hayek T; Zhao ZH; Roberts KG; Scheiner C; Friedman EA
Arterioscler Thromb; 1994 Sep; 14(9):1393-8. PubMed ID: 8068598
[TBL] [Abstract][Full Text] [Related]
6. Early elevation of lipoprotein(a) levels in chronic renal insufficiency.
De Lima JJ; Maranhão RC; Latrilha Mda C; Diament J; Romão JE; Krieger EM; Pileggi F
Ren Fail; 1997 Jan; 19(1):145-54. PubMed ID: 9044461
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression enhances atherogenicity of lipid profile after transplantation.
Quaschning T; Mainka T; Nauck M; Rump LC; Wanner C; Krämer-Guth A
Kidney Int Suppl; 1999 Jul; 71():S235-7. PubMed ID: 10412786
[TBL] [Abstract][Full Text] [Related]
8. Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations.
Isoniemi H; Tikkanen MJ; Ahonen J; Häyry P
Transpl Int; 1991 Sep; 4(3):130-5. PubMed ID: 1958276
[TBL] [Abstract][Full Text] [Related]
9. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients.
Raine AE; Carter R; Mann JI; Morris PJ
Nephrol Dial Transplant; 1988; 3(4):458-63. PubMed ID: 3140134
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in cyclosporin and azathioprine treated renal transplant patients.
McGrath LT; Treacy R; McClean E; Brown JH
Clin Chim Acta; 1997 Aug; 264(1):1-12. PubMed ID: 9267698
[TBL] [Abstract][Full Text] [Related]
11. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients.
Schorn TF; Kliem V; Bojanovski M; Bojanovski D; Repp H; Bunzendahl H; Frei U
Transpl Int; 1991 Jun; 4(2):92-5. PubMed ID: 1910436
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of lipoprotein A in renal transplant recipients.
Innocenti M; Lorenzetti M; Naldi F; Paleologo G; Pasquariello A; Marchetti P; Giannarelli R; Rindi P; Navalesi R; Rizzo G
Transplant Proc; 1998 Aug; 30(5):2048. PubMed ID: 9723386
[No Abstract] [Full Text] [Related]
14. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
[TBL] [Abstract][Full Text] [Related]
15. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population.
Potter JM; McWhinney BC; Sampson L; Hickman PE
Ther Drug Monit; 2004 Aug; 26(4):408-14. PubMed ID: 15257071
[TBL] [Abstract][Full Text] [Related]
16. [Coronary heart disease and lipoprotein (a): relationship with other lipid cardiovascular risk factors].
Nogués X; Sentí M; Pedro-Botet J; Molina L; Serrat R; Pons S; Rubiés-Prat J
Med Clin (Barc); 1992 Feb; 98(5):171-4. PubMed ID: 1532436
[TBL] [Abstract][Full Text] [Related]
17. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment.
Allegra A; Corica F; Ientile R; Corsonello A; Sparacino V; Accettola F; Caputo F; Macaione S; Buemi M
Magnes Res; 1998 Mar; 11(1):11-8. PubMed ID: 9595545
[TBL] [Abstract][Full Text] [Related]
18. Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?
Schena A; Di Paolo S; Morrone LF; Resta F; Stallone G; Schena FP
Clin Transplant; 2000 Apr; 14(2):139-46. PubMed ID: 10770419
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids.
Akman B; Uyar M; Afsar B; Sezer S; Ozdemir FN; Haberal M
Transplant Proc; 2007; 39(1):135-7. PubMed ID: 17275490
[TBL] [Abstract][Full Text] [Related]
20. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose.
von Ahsen N; Helmhold M; Eisenhauer T; Armstrong VW; Oellerich M
Eur J Clin Invest; 1996 Aug; 26(8):668-75. PubMed ID: 8872062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
